Changes in HIV Incidence among People Who Inject Drugs in Taiwan following Introduction of a Harm Reduction Program: A Study of Two Cohorts

PLoS Medicine

Volumn 11, Issue 4, 2014, Pages

  Huang, Yen Fang ^a,b   Yang, Jyh Yuan ^a   Nelson, Kenrad E ^c   Kuo, Hsu Sung ^a   Lew Ting, Chin Yin ^b   Yang, Chin Hui ^a   Chen, Chang Hsun ^a   Chang, Feng Yee ^a   Liu, Hui Rong ^a  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIAMORPHINE; METHADONE; MORPHINE; OPIATE;

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HEALTH EDUCATION; HEALTH PROGRAM; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL READMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OPIATE SUBSTITUTION TREATMENT; PROSPECTIVE STUDY; SEROCONVERSION; SYSTEMATIC REVIEW (TOPIC); TAIWAN; VIRUS LOAD; COHORT ANALYSIS; COMPLICATION; EPIDEMICS; HARM REDUCTION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; ISOLATION AND PURIFICATION; PROGRAM EVALUATION; RISK FACTOR; SUBSTANCE ABUSE; TRENDS; VIROLOGY; YOUNG ADULT;

ADULT; COHORT STUDIES; EPIDEMICS; FEMALE; HARM REDUCTION; HIV INFECTIONS; HIV SEROPREVALENCE; HIV-1; HUMANS; INCIDENCE; MALE; PROGRAM EVALUATION; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TAIWAN; YOUNG ADULT;

EID: 84900394521     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001625     Document Type: Article

References (39)

1. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. Lancet 372: 1733-1745.
2. World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS (2012) WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users: 2012 revision. Available: http://apps.who.int/iris/bitstream/10665/77969/1/9789241504379_eng.pdf. Accessed 1 January 2013.
3. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, et al. (2010) HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. Lancet 375: 1014-1028.
4. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, et al. (2010) HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376: 268-284.
5. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, et al. (2010) Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376: 285-301.
6. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R, (2011) Oral substitution treatment of injecting opioid uses for prevention of HIV infection. Cochrane Database Syst Rev 2011: CD004145.
7. MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, et al. (2012) Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 345: e5945.
8. Beyrer CB, Malinowska-Sempruch K, Kamarulzaman AK, Kazatchkine M, Sidibe M, et al. (2010) Time to act: A call for comprehensive responses to HIV in people who use drugs. Lancet 376: 551-563.
9. Wiessing L, Likatavicius G, Klempova D, Hedrich D, Nardone A, et al. (2009) Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. Am J Public Health 99: 1049-1052.
10. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M, (2007) Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam cohort studies among drug users. Addiction 102: 1454-1462.
11. Alistar SS, Owens DK, Brandeau ML, (2011) Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: A modeling analysis for Ukraine. PLoS Med 8: e1000423 doi:10.1371/journal.pmed.1000423.
12. Aceijas C, Stimson GV, Hickman M, Rhodes T, (2004) Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18: 2295-2303.
13. Chen YMA, Kuo SHS, (2007) HIV-1 in Taiwan. Lancet 369: 623-625.
14. Huang YF, Kuo HS, Lew-Ting CY, Tian F, Yang CH, et al. (2011) Mortality among a cohort of drug users after their release from prison: An evaluation of the effectiveness of a harm reduction program in Taiwan. Addiction 106: 1437-1445.
15. Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, et al. (2004) Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 190: 879-885.
16. Lyu SY, Su LW, Chen YM, (2011) Effects of education on harm-reduction programmes. Lancet 379: e28-e30.
17. Hall HT, Song R, Rhodes P, Prejean J, An Q, et al. (2008) Estimation of HIV incidence in the United States. JAMA 300: 520-529.
18. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance (2011) When and how to use assays for recent infection to estimate HIV incidence at a population level. Geneva: World Health Organization. Available: http://www.who.int/diagnostics_laboratory/hiv_incidence_may13_final.pdf. Accessed 1 July 2013.
19. Taiwan Ministry of Justice (2012) [Statistics of justice in 2010.] Available: http://www.moj.gov.tw/public/Attachment/13118133562.pdf. Accessed 30 September 2012.
20. Taiwan Centers for Disease Control Department of Health Executive Yuan (2012) [HIV/AIDS statistics.] Available: http://www.cdc.gov.tw/professional/info.aspx?treeid=BEAC9C103DF952C4&nowtreeid=2F13020F8A921CCB&tid=5250BA9AD485D6C3. Accessed 1 December 2012.
21. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS, (2004) Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 42: 2623-2628.
22. McWalter TA, Welte A, (2010) Relating recent infection prevalence to incidence with a sub-population of non-progressors. J Math Biol 60: 687-710.
23. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, Dobbs T, et al. (2012) Determination of mean recency period for estimation of HIV type 1 incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses 27: 265-273.
24. Suissa S, (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167: 492-499.
25. Agresti A, Coull BA, (1998) Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 52: 119-126.
26. Wood E, Kerr T, Marshall BD, Li K, Zhang R, et al. (2009) Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ Wood E 338: b1649.
27. Barrio G, Bravo MJ, Brugal MT, Diez M, Regidor E, et al. (2012) Harm reduction interventions for drug injectors or heroin users in Spain: expanding coverage as the storm abates. Addiction 107: 1111-1122.
28. Williams AB, McNelly EA, Williams AE, D'Aquila RT, (1992) Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care 4: 35-41.
29. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, et al. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. J Acquir Immune Defic Syndr 6: 1049-1056.
30. Serpelloni G, Carrieri MP, Rezza G, Morganti S, Gomma M, et al. (1994) Methadone treatment as a determinant of HIV risk reduction among injection drug users: A nested case-control study. AIDS Care 6: 215-220.
31. Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, et al. (1994) HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 8: 223-231.
32. Wodak A, Cooney A, (2006) Do needle syringe programs reduce HIV infection among injecting drug users: A comprehensive review of the international evidence. Subst Use Misuse 41: 777-813.
33. Tilson H, Aramrattana A, Bozzette S (2007) Preventing HIV infection among injecting drug users in high-risk countries: An assessment of the evidence. Washington (District of Columbia): Institute of Medicine.
34. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, et al. (2010) Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: A review of reviews. Addiction 105: 844-859.
35. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, et al. (2011) The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106: 1978-1988.
36. MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, et al. (2014) Interventions to prevent HIV and hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. Int J Drug Policy 25: 34-52.
37. Jürgens R, Ball A, Verster A, (2009) Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 9: 57-66.
38. Taylor A, Munro A, Allen E, Dunleavy K, Cameron S, et al. (2013) Low incidence of HCV amongst prisoners in Scotland. Addiction 108: 1296-1304.
39. Iguchi MY, London JA, Forge NG, Hickman L, Fain T, et al. (2002) Elements of well-being affected by criminalizing the drug user. Public Health Rep 117: S146-S150.